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Abstract 
Background: MicroRNAs are a class of small non-coding RNAs that are involved in many important physiological 
and pathological processes by regulating gene expression negatively. The purpose of this study was to investigate the 
effect of miR-32 on cell proliferation, migration and apoptosis and to determine the functional connection between 
miR-32 and FBXW7 in breast cancer.
Methods: In this study, quantitative RT-PCR was used to evaluate the expression levels of miR-32 in 27 breast cancer 
tissues, adjacent normal breast tissues and human breast cancer cell lines. The biological functions of miR-32 in MCF-7 
breast cancer cells were determined by cell proliferation, apoptosis assays and wound-healing assays. In addition, the 
regulation of FBXW7 by miR-32 was assessed by qRT-PCR, Western blot and luciferase reporter assays.
Results: MiR-32 was frequently overexpressed in breast cancer tissue samples and cell lines as was demonstrated 
by qRT-PCR. Moreover, the up-regulation of miR-32 suppressed apoptosis and promoted proliferation and migration, 
whereas down-regulation of miR-32 showed an opposite effect. Dual-luciferase reporter assays showed that miR-
32 binds to the 3′-untranslated region of FBXW7, suggesting that FBXW7 is a direct target of miR-32. Western blot 
analysis showed that over-expression of miR-32 reduced FBXW7 protein level. Furthermore, an inverse correlation was 
found between the expressions of miR-32 and FBXW7 mRNA levels in breast cancer tissues. Knockdown of FBXW7 
promoted proliferation and motility and suppressed apoptosis in MCF-7 cells.
Conclusions: Taken together, the present study suggests that miR-32 promotes proliferation and motility and sup-
presses apoptosis of breast cancer cells through targeting FBXW7.
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Background
Breast cancer is one of the most common malignant dis-
eases in women around the world and can be seriously 
harmful to women’s health and survival [1–3]. In more 
than 90% of patients with breast cancer initial invasion 
and distant metastasis are the major causes of death. The 
pathogenesis of breast cancer remains largely unknown. 
Molecular biology studies on breast cancer have 
shown that it is a complex process with multi-gene and 
multi-factor interactions that are mutually influenced like 
other malignancies [4, 5].
MicroRNAs (miRNAs) are a class of evolutionarily 
conserved, endogenous, small, about 20–22  nt nucleo-
tides in length, non-coding single-stranded RNAs that 
regulate gene expression by targeting the 3′ untranslated 
region (3′-UTR) of mRNAs [6, 7]. A growing number of 
studies have indicated that miRNA expression is associ-
ated with various tumors, including breast cancer [8–10]. 
MiR-32 is located on the 14th intron of gene C9orf5 [11]. 
Recently, miR-32 has been identified as an important 
regulator in tumorigenesis and it may act as a tumor sup-
pressor or an oncogene in different cancers [12–14]. Pre-
vious studies have shown that miR-32 was dysregulated 
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in breast cancer although its biological roles remain 
unclear [15, 16].
FBXW7 is one of the F-box protein family members, 
which can specifically identify and degrade substrate 
proteins in the ubiquitin–proteasome system (UPS). 
It is important in cell cycle regulation, transcriptional 
regulation, apoptosis and cell signal transduction, and is 
characterized by an approximately 40-amino acid motif, 
the F-box. Recent studies have shown that FBXW7 is 
believed to be a tumor suppressor that targets vari-
ous oncogenic proteins [17, 18]. FBXW7 mutations and 
deletions can cause chromosome instability and acceler-
ate the accumulation of cancer cell proliferation associ-
ated genes such as Myc, CyclinE and Aurora-A [19, 20]. 
FBXW7 has been identified in diverse human cancers, 
including T cell acute lymphoblastic leukemia, pancreatic 
cancer, endometrial cancer, and colon cancer [21–23]. 
The study of FBXW7 is very important to understand the 
mechanism of tumorigenesis and to provide new targets 
for cancer diagnosis and treatment.
Based on the information above, we demonstrated that 
miR-32 was highly expressed in both breast cancer tis-
sues and cell lines, and promoted the proliferation and 
migration and suppressed apoptosis of breast cancer 
cells. Moreover, we verified that miR-32 directly targeted 
FBXW7 through binding to the FBXW7-3′-UTR. Deple-
tion of FBXW7 by shFBXW7 could promote the prolif-
eration and motility,supress apoptosis of breast cancer 
cells. Furthermore, our results imply that high expression 
of miR-32 may contribute to the development of breast 
cancer through targeting FBXW7. Our findings will help 




Breast cancer tissues and adjacent normal breast tissues 
were obtained from 27 patients at the Nanfang Hospi-
tal of the Southern Medical University from February 
2013 to March 2015. All samples were snap-frozen in 
liquid nitrogen immediately after surgical removal and 
no patient had received chemotherapy or radiotherapy 
before surgery. The study was approved by the Eth-
ics Committee of the Nanfang Hospital of the South-
ern Medical University and samples were obtained with 
informed consent from all patients. Clinical pathological 
characteristics of all patients are summarized in Table 1.
Cell culture, construct and transfection
The normal human breast cell line MCF-10A and breast 
cancer cell lines MCF-7 and MDA-MB-231 were obtained 
from the Chinese Academy of Sciences Cell Bank (Shang-
hai, China). MCF-10A was incubated in DMEM/F12 
(1:1) (Hyclone, USA) with 10% fetal bovine serum (FBS, 
Hyclone). All breast cancer cells were cultured in DMEM 
(Hyclone, USA) supplemented with 10% FBS. Cells were 
cultured at 37 °C in a humidified atmosphere with 5% CO2. 
The miR-32 mimic, inhibitor, mimic-negative control (NC), 
inhibitor-NC and shFBXW7 oligo were obtained from 
GenePharma (Shanghai, China) and transfected into MCF-7 
cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. The 
RNA concentration of each transfection was 50 nM.
RNA isolation and real‑time PCR detection
Total RNA was extracted from tissues and cells using 
TRIzol reagent (Invitrogen, California, USA) and 
reversely transcribed into cDNA according to the man-
ufacturer’s instruction. Real-time PCR detection of 
miR-32 was conducted as reported by Francesca For-
nari et al. [24]. Detection of FBXW7 was performed via 
PrimeScriptTMRT reagent Kits (TaKaRa), and Permix Ex 
TaqII (TaKaRa) according to the manufacturer’s protocol. 
The primers used for real-time PCR detection include: 
miR-32-forward, 5′-GCG GCG TAT TGC ACA TTA 
CT-3′, and reverse, 5′-TCG TAT CCA GTG CAG GGT 
C-3′, U6-forward, 5′-CTC GCT TCG GCA GCA CA-3′, 
and reverse, 5′-AAC GCT TCA CGA ATT TGC GT-3′; 
FBXW7-forward, 5′-CCA CTG GGC TTG TAC CAT 
GTT-3′ and reverse, 5′-CAG ATG TAA TTC GGC GTC 
GTT-3′; β-actin-forward, 5′-TGA CGT GGA CAT CCG 
CAA AG-3′, and reverse, 5′- CTG GAA GGT GGA CAG 
CGA GG-3′. MiR-32 level was normalized with U6 and 
FBXW7 level was normalized with β-actin.
MTT assay
Cell proliferation was observed by the MTT assay. 
MCF-7 cells (1  ×  104) were plated into 96-well plates. 
Cell proliferation was assessed at the indicated time 
points after transfection as follows: 50 μl MTT (Keygen) 
working solution was added into the wells and the cells 
were incubated for 4 h at 37  °C, followed by removal of 
the culture medium and addition of 150  μl DMSO for 
20  min. The absorbance at 550  nm was measured in a 
Tecan Infinite Multiskan (Swiss).
Cell apoptosis assay
MCF-7 cells (1 × 105) were plated into 6-well plates and 
transfected with miR-32 mimic/inhibitor or mimic-NC/
inhibitor-NC. Forty-eight hours after transfection, cells 
were harvested and resuspended in 500 μl binding buffer. 
The cell suspension was incubated with 5  μl Annexin 
V-FITC for 15 min in a dark place. 50 μg/ml PI was added 
to each sample after which flow cytometry (C6; BD Bio-
sciences, Franklin Lakes, NJ, USA) was used to determine 
apoptosis of the MCF-7 cells.
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Wound‑healing assays
The ability of migration of breast cancer cells was inves-
tigated by wound-healing assays. After 48  h of miR-32 
mimic, inhibitor or mimic-NC/inhibitor-NC transfec-
tion, MCF-7 cells were obtained, plated at 8 × 104 cells/
well in 24 well plates and cultured until they formed a 
confluent monolayer. Wounds were scratched by 10  μl 
pipette tips. The MCF-7 cells were washed 3 times with 
PBS and then cultured in serum-free medium and photo-
graphed every 12 h by using QImagine Software.
Luciferase reporter assay
The 3′-UTR of FBXW7 mRNA which contains a putative 
target region for miR-32, was amplified from genomic 
DNA by PCR. The FBXW7 3′-UTR mutant construct 
was generated by overlap extension PCR. Fragments 
were inserted between the XhoI and NotI sites in the 
psiCHECK™-2 Dual Luciferase miRNA target expression 
vector (Promega, USA) to generate the recombinant vec-
tors FBXW7-wt and FBXW7-mut. Both insertions were 
verified by sequencing (Sangon, China). Co-transfection 
of the reporter vectors and miRNA (miR-32 mimic or 
mimic NC) was performed in MCF-7 cells using Lipo-
fectamine 2000. Forty-eight hours after transfection, 
luciferase and renilla signals were measured using the 
Dual Luciferase Reporter Assay Kit (Promega) according 
to the manufacturer’s protocol.
Western blotting
Cells were washed twice with Hanks’ balanced salt solu-
tion and lysed in RIPA lysis buffer (50  mM Tirs-Cl, pH 
7.4, 120  mM NaCl, 1% NP-40, 0.2% SDS, 1  mM EDTA 
and complete protease inhibitor), and centrifuged for 
20 min at 13,000g, 4 °C. The protein concentrations were 
subsequently determined using a BCA Protein Assay 
Kit (Beyotime, China) according to the manufacturer’s 
instructions. Protein samples (20  µg) were denatured 
with 4×  loading buffer (TAKARA) at 95  °C for 5  min. 
The polyvinylidene difluoride (PVDF; Life Technologies) 
membrane was blocked with phosphate-buffered saline 
(PBS) supplemented with 5% non-fat milk. Equal quanti-
ties of protein were subjected to SDS-PAGE and gels were 
Table 1 Association of  FBXW7 mRNA or miR-32 expression with  clinicopathological data from  breast cancer patients 
by quantitative PCR
Characteristics N miR‑32 FBXW7
Relative expression level P value Relative expression level P value
Age (year)
 ≤50 16 3.84 ± 2.84 0.100 1.11 ± 1.29 0.147
 >50 11 2.26 ± 1.37 0.49 ± 0.42
Tumor size (cm)
 ≤2 5 3.05 ± 0.59 0.969 0.56 ± 0.46 0.631
 >2 and ≤5 14 3.31 ± 3.13 0.66 ± 0.71
 >5 8 3.08 ± 1.94 1.01 ± 1.34
ER status
 Negative 7 4.05 ± 4.26 0.509 1.08 ± 1.48 0.454
 Positive 20 2.89 ± 1.45 0.62 ± 0.63
PR status
 Negative 7 1.88 ± 0.90 0.100 1.18 ± 1.42 0.324
 Positive 20 3.65 ± 2.66 0.59 ± 0.64
HER-2 status
 Negative 3 2.10 ± 1.41 0.885 0.38 ± 0.09 0.479
 Positive 24 3.22 ± 2.57 0.79 ± 0.96
Lymph node status
 Negative 12 3.82 ± 3.36 0.24 0.70 ± 1.14 0.817
 Positive 15 2.69 ± 1.28 0.78 ± 0.73
Clinical stage
 I–II 19 3.32 ± 2.85 0.695 0.85 ± 1.05 0.369
 III–IV 8 2.90 ± 1.13 0.49 ± 0.44
Ki-67
 Negative 2 3.27 ± 1.23 0.965 0.54 ± 0.23 0.749
 Positive 25 3.19 ± 2.53 0.76 ± 0.95
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transferred onto PVDF membranes. The PVDF mem-
brane was then incubated with the following anti-bodies: 
Anti-FBXW7 (1:500; Abcam) and anti-β-actin (1:2000; 
Cell Signaling Technology), at 4 °C overnight. The PVDF 
membrane was washed three times with PBS containing 
5% Tween (Sigma-Aldrich), and incubated with horse-
radish peroxidase-conjugated rabbit anti-mouse second-
ary antibody at room temperature for 2  h. An ECL kit 
was used to visualize the protein bands according to the 
manufacturer’s instructions. The relative protein expres-
sion levels were analyzed using Image-ProPlus 6.0 soft-
ware (Media Cybernetics, Inc., Rockville, MD, USA).
Statistical analysis
All statistical analyses were carried out using the SPSS 
18.0 statistical software package. Continuous variables 
were expressed as mean  ±  SD. Differences between 
groups were calculated with the Student’s t test. Pearson’s 
correlation was used to estimate the relationship between 
expression levels of miR-32 and FBXW7 mRNA. A two-
tailed P value test accompanied by a P value  <0.05 was 
considered statistically significant.
Results
Expression of miR‑32 is greatly increased in breast cancer 
tissues and cell lines
In order to evaluate the potential involvement of miR-
32 in breast cancer, the expression level of miR-32 was 
detected in 27 breast cancer tissues and corresponding 
adjacent non-tumor tissues by real-time PCR. As shown 
in Fig.  1a, miR-32 expression was greatly increased in 
20/27 breast cancer tissues when compared with adja-
cent non-tumor tissues (74.07%, P  <  0.05). The corre-
lation between miR-32 expression levels and clinical 
pathological characteristics are summarised in Table  1. 
In all specimens tested, we found an inverse correla-
tion between the expression of miR-32 and the level of 
FBXW7 mRNA (Fig.  1b, r  =  −0.431, P  =  0.0248). We 
also found that miR-32 was significantly elevated in 
tested breast cancer cell lines when compared with nor-
mal breast cell line MCF-10A (Fig.  1c). These results 
indicated that the expression of miR-32 was up-regu-
lated in breast cancer.
MiR‑32 promotes proliferation and migration of breast 
cancer cells
In order to explore the involvement of miR-32 in breast 
cancer development and progression, miR-32 mimic, 
inhibitor or NC oligonucleotides were transfected into 
MCF-7 cells to restore its expression level as tested by 
real-time PCR (Fig. 2a, b). The impact of miR-32 on cell 
proliferation and viability was analyzed by MTT assay. 
As shown in Fig. 2c, cells transfected with miR-32 mimic 
showed significantly higher optical density (OD) values 
at 550 nm than the NC group from day 2 until day 4, in 
a time dependent manner. The miR-32 inhibitor group 
displayed lower OD values and cell proliferation was sig-
nificantly suppressed in this group (Fig. 2d). The effect of 
miR-32 on the migration of breast cancer cells was char-
acterized by a wound-healing assay, which showed that 
up-regulation of miR-32 could significantly promote cell 
migration and down-regulation of miR-32 could suppress 
cell migration (Fig. 2e, f ). Taken together, miR-32 is able 
to promote the proliferation and migration of breast can-
cer cells in vitro.
MiR‑32 inhibits apoptosis of breast cancer cells
MiR-32 mimic, inhibitor or NC miRNA oligonucleotides 
were transfected into MCF-7 cells and apoptosis was 
determined by FACS analysis. As shown in Fig. 3a, apop-
tosis in miR-32 mimic transfected cells was significantly 
inhibited when compared with the NC group. Down-reg-
ulation of miR-32 had the opposite effect (Fig. 3b). These 
results suggested that miR-32 may affect apoptotic path-
ways in regulating tumorigenicity.
FBXW7 is a novel target gene of miR‑32 in MCF‑7 cells
To find the underlying mechanisms of miR-32 in 
breast cancer, we investigated potential targets of 
miR-32 using prediction software (TargetScan, PicTa, 
miRanda, the miRBase, DIANA TarBase). Bioinfor-
matic analyses predicted that FBXW7 was a poten-
tial target of miR-32. To validate whether miR-32 
might mediate the decay of FBXW7 mRNA via the 
3′-UTR, we subcloned FBXW7 mRNA 3′-UTR into 
psiCHECK™-2 luciferase reporter construct (FBXW7-
wt). A mutant form of FBXW7 mRNA 3′-UTR was 
generated through mutating the binding site of miR-32 
(FBXW7-mut) (Fig.  4a). Next, these constructs were 
transfected into MCF-7 cells with miR-32 mimic or 
NC miRNA. The luciferase assay showed that miR-32 
remarkably down-regulated the luciferase activity of 
the FBXW7-wt construct, while the luciferase activ-
ity of FBXW7-mut in MCF-7 cells was unchanged 
(Fig.  4b). As shown in Fig.  4c, d, FBXW7 expres-
sion was significantly decreased in miR-32 mimic 
transfected cells when compared with the NC group 
whatever the mRNA or protein level. These data dem-
onstrated that miR-32 can down regulate FBXW7 
expression by directly targeting its 3′-UTR.
FBXW7 inhibits cell growth and cell migration
We also evaluated the expression of FBXW7 in 27 paired 
breast cancer and adjacent normal breast tissues by 
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qRT-PCR. Data showed that the average level of FBXW7 
mRNA was significantly decreased in 19/27 breast can-
cer tissues when compared with corresponding normal 
tissues (70.37%, P  <  0.05) (Fig.  5a). Moreover, FBXW7 
mRNA levels in breast cancer cases were inversely cor-
related with miR-32 expression. MCF-7 cells were trans-
fected with FBXW7 shRNA or NC to further investigate 
whether the effect of miR-32 on cell proliferation, migra-
tion and apoptosis of MCF-7 cells was via targeting 
FBXW7 (Fig.  5b). As shown in Fig.  5c, the MTT value 
of cells transfected with shRNA was significantly higher 
than that of cells transfected with NC 2 days post-trans-
fection. The results showed that suppression of FBXW7 
expression by shRNA promoted cell migration and inhib-
ited cell apoptosis when compared with the NC group 
(Fig. 5d, e). Altogether, our findings suggested that miR-
32 promotes cell growth and migration of breast cancer 
cells, at least in part, by targeting FBXW7.
Interference of FBXW7 restored miR‑32‑mediated breast 
cancer cell growth and migration
To this end, the FBXW7-targeting shRNA oligo were 
employed to deplete endogenous FBXW7 in breast cancer 
cells. NC, miR-32 inhibitor and FBXW7 shRNA oligo were 
transfected independently or simultaneously into MCF-7 
cells. As shown in Fig. 6a, b, depletion of FBXW7 by trans-
fection of shFBXW7 oligo significantly promote the pro-
liferation and migration of MCF-7 cells compared with 
NC group. However, the proliferation and migration of 
MCF-7 cells were restored after co-transfection with miR-
32 inhibitor. Then, we found that MCF-7 cells exhibited 
distinct responses to FBXW7, with regard to miR-32-me-
diated anti-apoptotic effect. Whereas depletion of FBXW7 
restored the apoptotic response in miR-32-inhibiting 
MCF-7 cells (Fig.  6c). These findings inferred that miR-
32 promotes cell proliferation, migration, and suppresses 
apoptosis by inhibiting the expression of FBXW7.
a
b c
Fig. 1 MiR-32 is up-regulated in breast cancer samples and cell lines. a Expression levels of miR-32 were up-regulated in 20 breast cancer tissues 
when compared with adjacent normal tissues. b In 19 breast cancer tissues and corresponding adjacent non-tumor tissues, miR-32 has a negative 
correlation with FBXW7 mRNA expression. c The expression level of miR-32 was up-regulated in MCF-7 and MDA-MB-231 cell lines when compared 
with MCF-10A. Bars represent the mean of three independent experiments performed three times ±SD. *P < 0.01
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Fig. 2 Effect of miR-32 expression on growth and migration in breast cancer cells. a, b QRT-PCR of miR-32 expression in mimic/inhibitor or NC 
transfected MCF-7 cells. U6 was used as an internal control. c, d MTT analysis of MCF-7 growth following transfection with miR-32 mimic/inhibitor or 
NC. MiR-32 mimic promotes cell proliferation and inhibitor suppresses cell growth. e, f Wound-healing assay showing that gain of miR-32 promotes 
cell migration and loss of miR-32 suppresses cell migration. Each assay was repeated three times. *P < 0.05
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Fig. 3 Effects of miR-32 expression on apoptosis in breast cancer cells. a, b MiR-32 mimic suppresses MCF-7 cell apoptosis and miR-32 inhibi-
tor induces cell apoptosis. Cell apoptosis was analyzed by Annexin V-FITC analysis. Data represents the mean of three independent assays ±SD. 
*P < 0.05
Fig. 4 MiR-32 targeted FBXW7. a The miR-32 binding site in FBXW7 3′-UTR, located 286-292 bp upstream of the FBXW7 3′-UTR. b The relative 
luciferase activity in miR-32 mimic group and NC group. c The relative expression of FBXW7 in miR-32 mimic transfected group and NC group. Bars 
represent the mean of three independent experiments performed three times ±SD. d Western blot analysis of FBXW7 protein levels in miR-32 
overexpressing and NC cells. *P < 0.05
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Discussion
Since dysregulation of specific miRNAs have been found 
in tumor biopsies and body fluids, accumulating studies 
have revealed that miRNAs can function as tumor sup-
pressors or oncogenes in the development and progres-
sion of breast cancer [25–27].
It has been observed that high miR-32 levels were pre-
sent in some tumor but low levels in others. For exam-
ple, miR-32 in lung cancer is significantly down regulated 
[28], on the contrary, in renal and prostate cancer tissue 
the level of miR-32 is significantly raised and associated 
with the prognosis of patients [29, 30]. Moreover, it is 
believed that mature miR-32 has divergent effects on the 
development of cancer, such as the elevated expression 
of miR-32 significantly inhibits the proliferation, migra-
tion and invasion of the SGC-7901 gastric cancer cell line 
[12]. Two other studies showed that miR-32 suppresses 
osteosarcoma cell proliferation and invasion through 
regulating Sox9 expression [13] and promotes CRC cells 
proliferation, migration, and invasion and reduces apop-
tosis by targeting PTEN [14]. In conclusion, miR-32 may 
play a different role in different tumor types. In this study, 
we described the biological significance and the effects of 
miR-32 dysregulation on cell proliferation, migration and 
Fig. 5 The effect of FBXW7 depletion in MCF-7 cells. a Expression level of FBXW7 was down-regulated in 19 breast cancer tissues compared with 
adjacent normal tissues. b The expression level of FBXW7 in transfected shRNA MCF-7 cells. c MTT analysis showed that FBXW7 depletion promotes 
cells proliferation. d Wound-healing assay showed that loss of FBXW7 promotes cell migration. e FBXW7 depletion suppresses MCF-7 cell apoptosis. 
Data represents the mean of three independent assays ±SD. *P < 0.05
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apoptosis in human breast cancer cells. Furthermore, we 
identified FBXW7 as a direct target of miR-32 in breast 
cancer cell lines.
F-box and WD-40 domain protein 7 (FBXW7) is one of 
the F-box protein family members, which can identify the 
target proteins of the SCF ubiquitin ligase [31]. It plays 
an important role in many physiological and pathological 
processes, such as cell growth, differentiation, apoptosis, 
and cellular signal transduction [32]. Recent studies have 
demonstrated that FBXW7 is a tumor suppressor. Dele-
tions and mutations of FBXW7 have been identified in 
a variety of cancers including colorectal cancer, gastric 
cancer, ovarian cancer, neuroglioma and breast cancer 
[23, 33]. Iwatsuki et al. [34] found that a low expression 
of FBXW7 correlated with a poor prognosis in colorec-
tal cancer patients and indicated that FBXW7 could 
serve as a prognostic factor. Milne et  al. [35] reported 
that loss of FBXW7 played a role in gastric carcinogen-
esis and Li et  al. also found that miR-223, which acts 
as oncogene, regulated FBXW7in human gastric can-
cer [36]. In addition, Gong et al. [37] demonstrated that 
miR-25 promoted gastric cancer progression by directly 
Fig. 6 The effect of FBXW7 depletion on miR-32-mediated breast cancer chemoresistance. a The proliferation rate of MCF-7 cells were detected 
through MTT assay at different time periods after transfection of miR-32 inhibitor and FBXW7 shRNA independently or simultaneously compared 
with NC group. b Statistical analysis of the proportion of healing compared with NC group. c Annexin V/PI analysis was performed to determine cell 
apoptosis in the indicated groups. Data represents the mean of three independent assays ±SD. (*P < 0.05)
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down-regulating FBXW7 expression. FBXW7 can also 
bind directly to multiple transcriptional activators and 
proto-oncogenes including cyclin E, c-Myc and Notch for 
ubiquitination and subsequent degradation [32, 38, 39]. 
Studies on FBXW7 as tumor suppressor are extremely 
important to understand tumorigenesis as it can act 
as a therapeutic target as well as a diagnostic marker in 
cancers.
In the present study, we have demonstrated that the 
expression of miR-32 was increased in the majority of 
breast cancer tissues and in breast cancer cell lines. Fur-
ther functional analysis suggested the involvement of 
miR-32 in the progression of breast cancer, and forced 
expression of miR-32 significantly promoted prolifera-
tion and migration as well as repressed cell apoptosis in 
breast cancer cell line MCF-7. Our results reveal that 
miR-32 may act as a tumor promoter to participate in 
the progression of breast cancer. However, we failed to 
find a correlation between miR-32 and PR, ER and HER2 
expression in the tissues of breast cancer patients, the 
reason might be that miR-32 has nothing to do with the 
involved molecular pathways of ER and PR. Our data 
reflect the heterogeneous nature of tumors and indicate 
that miR-32 functions are tumor-specific.
According to the results of TargetScan and miRanda 
analysis, we identified FBXW7 as a target gene of miR-
32 which was partly verified by the inhibition of FBXW7 
mRNA expression in mimic-transfected MCF-7 cells 
in  vitro. We found an inverse correlation between the 
expression of miR-32 and the level of FBXW7 mRNA in 
breast cancer tissues. Our study showed that inhibition 
of FBXW7 mRNA expression could promote the prolif-
eration and migration, and suppress apoptosis of breast 
cancer cells. The dual luciferase assay further confirmed 
that FBXW7 was a direct target of miR-32. MiR-32 was 
sufficiently strong enough to inhibit FBXW7 via direct 
binding to the FBXW7 3′-UTR region.
There are some limitations of this study that should be 
noted. The clinical tissue information comes mainly from 
the clinical stage, cannot cover all molecular subtypes of 
breast cancer, and it is difficult to reflect the overall het-
erogeneity and individual differences. As comprehensive 
data on miR-32 expression is currently unavailable, fur-
ther studies are needed to reveal the exact role of miR-32 
in breast cancer and subtypes in much larger popula-
tions. Further functional analyses are also needed to vali-
date the possible utility of miR-32.
Conclusion
In conclusion, the present study assessed the expression 
and functions of miR-32 in breast cancer. In addition, 
miR-32 induced down-regulation of FBXW7 and regu-
lated the proliferation, migration and apoptosis capability 
of breast cancer cells. These findings indicate that miR-32 
may serve as a tumor gene in breast cancer, at least partly 
via directly targeting FBXW7, and may therefore act as 
a potential candidate for miRNA-based therapy against 
breast cancer.
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